Insights into the Worldwide BRAF Mutated Non-Small Cell Lung Cancer (2018 to 2030) - Organize Sales and Marketing Efforts by Identifying the Best Opportunities - ResearchAndMarkets.com

DUBLIN--()--The "BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the BRAF Mutated NSCLC, historical and forecasted epidemiology as well as the BRAF Mutated NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The BRAF Mutated NSCLC market report provides current treatment practices, emerging drugs, BRAF Mutated NSCLC market share of the individual therapies, current and forecasted BRAF Mutated NSCLC market size from 2017 to 2030 segmented by seven major fmarkets. The Report also covers current BRAF Mutated NSCLC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.

There are several mutation associated with NSCLC but the most common are EGFR, KRAS, ROS-1 , BRAF , BRAF , PD-L1 expression and others. Among all the mutations BRAF accounted for approximately 5% of the total cases of NSCLC.

BRAF mutated NSCLC is now recognized as a rare form of lung cancer. The biologic behavior of BRAF mutated lung tumors tends to be more aggressive. The one unique aspects of BRAF mutated NSCLC, which differentiates it from other molecularly driven tumors such as EGFR, ALK, and ROS1, is that patients with BRAF V600E-mutant NSCLC tend to be patients with a smoking history. The BRAF gene encodes for a serine/threonine kinase that belongs to the RAS-RAF-MEK-ERK axis that regulates cellular growth.

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the BRAF Mutated NSCLC market.
  • To understand the future market competition in the BRAF Mutated NSCLC market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for BRAF Mutated NSCLC in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for BRAF Mutated NSCLC market.
  • To understand the future market competition in the BRAF Mutated NSCLC market.

Key Topics Covered:

1. Key Insights

2. Executive Summary of BRAF Mutated NSCLC

3. SWOT Analysis of BRAF Mutated NSCLC

4. BRAF NSCLC: Market Overview at a Glance

4.1. Total Market Share (%) Distribution of NSCLC in 2017: By Country

4.2. Total Market Share (%) Distribution of NSCLC in 2030: By Country

5. BRAF Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview

6. Diagnosis of NSCLC

6.1. Diagnostic Algorithm for NSCLC

6.2. Stages of NSCLC

6.3. Staging System

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.4. The United States Epidemiology

8. EU-5 Epidemiology

8.1. Germany

8.2. France

8.3. Italy

8.4. Spain

8.5. The United Kingdom

9. Japan Epidemiology

10. Current Treatment Practices: NSCLC

10.1. Advanced/Metastatic NSCLC Treatment Algorithm

10.2. Chemotherapy

10.3. Targeted Therapy

10.4. Immunotherapy

10.5. Surgery

10.6. Radiation Therapy

10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC

11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020

11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018

11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of NSCLC

13. Key Endpoints in NSCLC Clinical Trials

14. Marketed Therapies

15. Key Cross

15.1. Tafinlar(Dabrafenib) in Combination with Mekinist(Trametinib): Novartis

15.1.1. Product Description

15.1.2. Regulatory Milestones

15.1.3. Other Developmental Activities

15.1.4. Pivotal Clinical Trials

16. Emerging Therapies

17. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis

17.1. Key Findings

17.2. Market Outlook: 7MM

18. BRAF Mutation - Market Size

18.1. Total Market Size of BRAF NSCLC in the 7MM

18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM

18.3. United States Market Size

18.3.1. Total Market size of BRAF NSCLC in the United States

18.4. EU-5 Market Size

18.4.1. Germany Market Size

18.4.2. France Market Size

18.4.3. Italy Market Size

18.4.4. Spain Market Size

18.4.5. United Kingdom Market Size

18.5. Japan Market Size

18.5.1. Total Market size of BRAF NSCLC in Japan

19. Market Access and Reimbursement of BRAF Mutated NSCLC Therapies

20. Market Drivers of BRAF Mutated NSCLC

21. Market Barriers of BRAF Mutated NSCLC

22. Appendix

23. Report Methodology

24. Publisher Capabilities

25. Disclaimer

26. About the Publisher

Companies Mentioned

  • Hoffmann-La Roche
  • Novartis
  • Pfizer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/c6wfrw

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900